Does ponatinib cross the blood-brain barrier?-Reference-Cited by-同舟云学术

Does ponatinib cross the blood-brain barrier?

Published:2016-06-28 Issue:3 Volume:179 Page:497-498
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Abid Muhammad B.¹,De Mel Sanjay¹

Affiliation:

1. Department of Haematology/Oncology; National University Cancer Institute Singapore (NCIS); Singapore

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14222/fullpdf

Reference6 articles.

1. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias;Cortes;New England Journal of Medicine,2013

2. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia;Foà;Blood,2011

3. Isolated central nervous system relapse in two patients with BCR-ABL-positive acute leukemia while receiving a next-generation tyrosine kinase inhibitor;Gaur;In Vivo,2014

4. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies;Jabbour;Cancer,2010

5. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia;Porkka;Blood,2008

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Moving Toward a Chemotherapy-Free Approach for Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia;Advances in Oncology;2023-05

2. Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study;Technology in Cancer Research & Treatment;2023-01

3. Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer;Technology in Cancer Research & Treatment;2023-01

4. Management of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia;Pathogenesis and Treatment of Leukemia;2023

5. Prophylaxis and Treatment of Central Nervous System (CNS) Acute Lymphoblastic Leukemia;Clinical Management of Acute Lymphoblastic Leukemia;2022